华检医疗(01931.HK)公开发售超购约2.212倍预期7月12日上市
格隆汇7月11日丨华检医疗(01931.HK)公布,全球发售3.334亿股,其中香港发售约3334万股,国际发售约3亿股;发售价每股3.07港元;每手1,000股;预期2019年7月12日上市。
公告显示,公开发售适度超额认购,相等于根据香港公开发售初步可供认购的香港发售股份总数33,340,000股的约2.212倍。
国际发售获足额认购。根据国际发售分配予合共100名承配人的最终发售股份数目约为3亿股发售股份,相当于全球发售项下发售股份总数的90%(于任何超额配股权获行使前)。
公告称,所得款项净额约为9.32亿港元。其中,约49.6%用于结清收购威士达60%股权的现金代价的未偿还结余;约32.9%,用于根据收购事项向公司及威士达现有股东派付部分股息;约6.8%用于在分销业务项下扩大客户群;约3.5%用于继续研发自有品牌产品;约2.6%用于扩展分销业务并提升分销价值链;约4.6%用于营运资金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.